Modafinil Milpharm (Modafinil)

Modafinil is indicated for disorders characterized by excessive daytime sleepiness, acting on central nervous system pathways that regulate wakefulness.

• Narcolepsy: reduces the frequency of sleep attacks and improves daytime alertness.
• Obstructive sleep apnea‑related excessive daytime sleepiness: enhances wakefulness when used alongside primary sleep‑apnea therapy.
• Shift work disorder: helps maintain alertness during scheduled work hours that occur at night or early morning.

• Modafinil promotes wakefulness primarily by inhibiting the reuptake of dopamine, leading to increased extracellular dopamine concentrations in the brain. It also influences other neurotransmitter systems, including orexin, histamine, and norepinephrine pathways, which collectively enhance cortical activation and reduce sleep propensity. These actions result in heightened alertness without the pronounced stimulant effects typical of classic sympathomimetic agents.

Modafinil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Insomnia: difficulty initiating or maintaining sleep.
• Dry mouth: reduced salivation.
• Anxiety: feelings of nervousness or tension.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe skin reactions requiring immediate medical attention.
• Psychiatric symptoms: new or worsening depression, hallucinations, or mania.
• Cardiovascular events: chest pain or arrhythmias in susceptible individuals.

When prescribing Modafinil, clinicians should consider several precautionary measures to ensure safe use.

• Cardiovascular assessment: evaluate history of hypertension, arrhythmia, or heart disease.
• Psychiatric evaluation: screen for depression, bipolar disorder, or psychosis.
• Liver function: monitor in patients with hepatic impairment.
• Drug dependence: avoid in individuals with a history of substance abuse.
• Pregnancy and lactation: use only if potential benefit justifies potential risk.
• Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Modafinil can interact with other medicines, altering their effectiveness or safety profile.

Major Interactions (Avoid)

• CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin): may markedly reduce Modafinil plasma levels.
• CYP2C19 inhibitors (e.g., fluvoxamine): can increase Modafinil exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: Modafinil may decrease hormonal efficacy, requiring alternative contraception.
• Anticoagulants (e.g., warfarin): potential alteration of INR, necessitating closer monitoring.
• Antidepressants (e.g., SSRIs): may increase risk of serotonin syndrome, observe for symptoms.